Cargando…
Shortage of Nab-paclitaxel in Japan and around the World: Issues in Global Information Sharing
There was a global shortage of nab-paclitaxel (Abraxane(Ⓡ)), a major antineoplastic agent, for a long period (from October 2021 to June 2022) because of manufacturing problems. Japan was one of the first affected countries by the depletion, and the medical institutes started to save the use of the d...
Autores principales: | Oura, Mitsuaki, Saito, Hiroaki, Nishikawa, Yoshitaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169259/ https://www.ncbi.nlm.nih.gov/pubmed/37179729 http://dx.doi.org/10.31662/jmaj.2022-0179 |
Ejemplares similares
-
First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
por: Funaishi, Kunihiko, et al.
Publicado: (2017) -
nab-Paclitaxel for the treatment of pancreatic cancer
por: Kim, George
Publicado: (2017) -
Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
por: Kokubu, Hiraku, et al.
Publicado: (2023) -
Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo
por: Saito, Nobuhiro, et al.
Publicado: (2018) -
A Real-World Efficacy of Nab-Paclitaxel Monotherapy in Metastatic Breast Cancer
por: Kim, Jung Sun, et al.
Publicado: (2022)